NCT07649057
A Study of a Urine Test to Detect Colorectal Cancer
Recruiting
Not specifiedAges 18+ObservationalMemorial Sloan Kettering Cancer CenterInvestigator-initiated
~210 participants
Updated 2026-06-15 on ClinicalTrials.gov
What's tested:3-metabolite biosensor
At a glance
Recruiting sites
1 of 4 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Sensitivity of 3-metabolite biosensor
Measured over up to 1 year
Conditions
Where it's being run
4 sites across 4 statesNew York1
Ghana1
South Africa1
Tanzania1
Study leadership
- Peter Kingham, MD · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Patient presents with one of the following:
Patients with symptoms of CRC (such as rectal bleeding for a week) -OR-
Patients who present for a screening colonoscopy -OR-
Has received one of the following within 3 weeks of the planned urine collection
Patients with a pathologic diagnosis of CRC either by colonoscopy or resection specimens -OR-
Patients with colonoscopy demonstrating adenomatous polyps -OR-
Patients with colonoscopy demonstrating no colon or premalignant or malignant pathology
Age ≥ 18
Willingness to participate in the study
What this trial measures
- Sensitivity of 3-metabolite biosensorup to 1 year
The study will validate a 3-metabolite biosensor that identifies participants with colorectal cancer (CRC) and precancerous polyps in Ghana, Tanzania and South Africa. The primary aim is to show that the sensitivity and specificity in other regions are as good as the Nigerian estimates (i.e. 90% and 80% respectively).